Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. Among authors: paul c. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council.
Bissonnette R, Simpson E, Eichenfield LF, Guttman-Yassky E, Silverberg JI, Beck LA, Mija L, Thyssen JP, Bieber T, Kabashima K, Siegfried E, Stingl G, van de Kerkhof P, Yosipovitch G, Paul C, Paller AS. Bissonnette R, et al. Among authors: paul c. J Eur Acad Dermatol Venereol. 2024 Mar;38(3):e291-e295. doi: 10.1111/jdv.19627. Epub 2023 Nov 22. J Eur Acad Dermatol Venereol. 2024. PMID: 37943170 No abstract available.
A plain language summary of what freedom from disease means to people with psoriasis according to doctors, nurses, and people with psoriasis.
Ee IV, Deprez E, Egeberg A, Conrad C, Corazza V, Donati L, Lambert J, Lăpădatu R, Meyer A, Paul C, Penzer-Hick R, Stephen K, der Zon JV, Bewley A. Ee IV, et al. Among authors: paul c. J Comp Eff Res. 2023 Apr;12(4):e220206. doi: 10.57264/cer-2022-0206. Epub 2023 Feb 28. J Comp Eff Res. 2023. PMID: 36852761 Free PMC article.
Freedom from disease in plaque psoriasis: Comparing the perceived importance of voting round 2 statements from a Delphi consensus of patients, physicians and nurses.
van Ee I, Deprez E, Egeberg A, Conrad C, Corazza V, Donati L, Lambert J, Lăpădatu R, Meyer A, Paul C, Penzer-Hick R, Stephen K, van der Zon J, Bewley A. van Ee I, et al. Among authors: paul c. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e16-e19. doi: 10.1111/jdv.19397. Epub 2023 Aug 25. J Eur Acad Dermatol Venereol. 2024. PMID: 37556673 No abstract available.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
Strober B, Paul C, Blauvelt A, Thaçi D, Puig L, Lebwohl M, White K, Vanvoorden V, Deherder D, Gomez NN, Eyerich K. Strober B, et al. Among authors: paul c. J Am Acad Dermatol. 2023 Sep;89(3):486-495. doi: 10.1016/j.jaad.2023.04.063. Epub 2023 May 12. J Am Acad Dermatol. 2023. PMID: 37182701 Free article. Clinical Trial.
Price variability of TNF-α inhibitor biosimilars among European countries.
Geat D, Gisondi P, Maurelli M, Puig L, Paul C, Thaçi D, Iversen L, Bellinato F, Girolomoni G. Geat D, et al. Among authors: paul c. J Eur Acad Dermatol Venereol. 2023 Dec 18. doi: 10.1111/jdv.19756. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 38108512 No abstract available.
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, Paul C, Gomez M, Wegner S, Personke Y, Kreimendahl F, Chen Y, Angsana J, Leung MWL, Eyerich K. Schäkel K, et al. Among authors: paul c. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2016-2027. doi: 10.1111/jdv.19236. Epub 2023 Jul 18. J Eur Acad Dermatol Venereol. 2023. PMID: 37262309 Clinical Trial.
The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study.
Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Stratigos A, Trakatelli M, Puig L; EADV Burden of Skin Diseases Project Team. Richard MA, et al. Among authors: paul c. J Eur Acad Dermatol Venereol. 2023 Oct;37 Suppl 7:17-24. doi: 10.1111/jdv.18916. J Eur Acad Dermatol Venereol. 2023. PMID: 37806003
2,130 results